PMID- 1586984
OWN - NLM
STAT- MEDLINE
DCOM- 19920619
LR  - 20190827
IS  - 0344-5704 (Print)
IS  - 0344-5704 (Linking)
VI  - 30
IP  - 1
DP  - 1992
TI  - A randomised phase II study of carmustine alone or in combination with tumour 
      necrosis factor in patients with advanced melanoma.
PG  - 73-6
AB  - Laboratory data suggest a synergistic interaction between carmustine (BCNU) and 
      tumour necrosis factor (TNF) in melanoma. We therefore studied the activity of 
      200 mg/m2 BCNU given alone or in combination with 88 micrograms/m2 recombinant 
      human TNF-alpha (rhTNF alpha) as a daily i.v. infusion for 5 days at 48-day 
      intervals to patients with metastatic melanoma. In this randomised phase II 
      trial, the rate of response to BCNU alone was 20% [95% confidence interval (CI), 
      2%-38%], and this was not improved by the addition of TNF (response rate, 10.5%; 
      95% CI, 1.3%-33%). Toxicity was higher in the combination arm, and there was no 
      difference in survival.
FAU - Jones, A L
AU  - Jones AL
AD  - Department of Medicine, Royal Marsden Hospital, London, U.K.
FAU - O'Brien, M E
AU  - O'Brien ME
FAU - Lorentzos, A
AU  - Lorentzos A
FAU - Viner, C
AU  - Viner C
FAU - Hanrahan, A
AU  - Hanrahan A
FAU - Moore, J
AU  - Moore J
FAU - Millar, J L
AU  - Millar JL
FAU - Gore, M E
AU  - Gore ME
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Cancer Chemother Pharmacol
JT  - Cancer chemotherapy and pharmacology
JID - 7806519
RN  - 0 (Recombinant Proteins)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - U68WG3173Y (Carmustine)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use
MH  - Carmustine/administration & dosage/blood/*therapeutic use
MH  - Drug Administration Schedule
MH  - Drug Evaluation
MH  - Drug Synergism
MH  - Female
MH  - Humans
MH  - Infusions, Intravenous
MH  - Male
MH  - Melanoma/*drug therapy
MH  - Middle Aged
MH  - Recombinant Proteins/administration & dosage/therapeutic use
MH  - Tumor Necrosis Factor-alpha/administration & dosage/*therapeutic use
EDAT- 1992/01/01 00:00
MHDA- 1992/01/01 00:01
CRDT- 1992/01/01 00:00
PHST- 1992/01/01 00:00 [pubmed]
PHST- 1992/01/01 00:01 [medline]
PHST- 1992/01/01 00:00 [entrez]
AID - 10.1007/BF00686489 [doi]
PST - ppublish
SO  - Cancer Chemother Pharmacol. 1992;30(1):73-6. doi: 10.1007/BF00686489.